With the advancement of therapeutic strategies, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) and immune checkpoint inhibitors were used for the first-line treatment of patients with lung cancer [30, 31]. This evidence concerns the gene EGFR and lung carcinoma.